Company: AEMD
Filing Date: 2025-08-29
Form Type: S-1/A
Source: 0001683168-25-006537
Chunk: 37

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-29
Form: S-1/A
Chunk 37
---
ities,
Inc. then owned 100% of each company. Upon completion of the transaction, Bishop Equities, Inc. was renamed Aethlon Medical, Inc. Our
executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360.
Our website address is www.aethlonmedical.com. The information contained on, or that can be accessed through, our website is not part
of, and is not incorporated into, this prospectus, and you should not rely on any such information in making the decision of whether to
purchase our securities.

| 17 |

Smaller Reporting Company

We are
a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies.

<div align='center'>The Offering</div>

| Common stock offered by the Selling Securityholders | Up to 1,550,000 shares of common stock issuable upon exercise of the Inducement Warrants.                                              |
| Common stock offered by us                          | 4,566,210                                                                                                                              
 shares.                                                                                                                                |
| Pre-funded warrants                                 | We are also offering                                                                                                                   
 to those purchasers, if any, whose purchase of common stock in the Company Offering would otherwise result in such purchaser, together 
 with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock immediately       
 following the consummation of this offering, the opportunity, in lieu of purchasing common stock, to purchase pre-funded warrants      
 to purchase up to 4,566,210 shares of our common stock. For each pre-funded warrant we sell, the number of shares of                   
 common stock we are offering will be decreased on a one-for-one basis. The purchase price of each pre-funded warrant                   
 will equal the price per share at which the shares of common stock and accompanying warrants to purchase common stock are being sold   
 to the public in the Company Offering, minus $0.001, and the exercise price of each pre-funded warrant will be $0.001 per share of     
 common stock.                                                                                                                          
 Each pre-funded warrant will be exercisable                                                                                            
 immediately upon issuance and will not expire. This prospectus also relates to the offering of the shares of common stock issuable     
 upon